Rosenqvist E, Høiby E A, Bjune G, Aase A, Halstensen A, Lehmann A K, Paulssen J, Holst J, Michaelsen T E, Nøkleby H, Frøholm L O, Closs O
Department of Vaccinology, National Institute of Public Health, Oslo, Norway.
Dev Biol Stand. 1998;92:323-33.
Three different formulations of an outer membrane vesicle (OMV) vaccine against group B meningococcal disease have been prepared and tested for immunogenicity and reactogenicity in adult volunteers. The vaccines were prepared with or without aluminium hydroxide and serogroup C-polysaccharide (C-ps). Doses from 12.5 to 100 micrograms protein were given twice at a six weeks' interval. All three formulations were well tolerated and highly immunogenic, inducing bactericidal and opsonizing antibodies in humans. Adsorption of OMVs to aluminium hydroxide reduced the pyrogenicity in rabbits. The differences in immunogenicity between the formulations were relatively small, but after the second dose a stronger booster response was observed when the vaccines were adsorbed. Thus, a formulation with OMVs and C-ps represents a safe and highly immunogenic vaccine, even without aluminium hydroxide.
已制备出三种不同配方的抗B群脑膜炎球菌病外膜囊泡(OMV)疫苗,并在成年志愿者中测试了其免疫原性和反应原性。这些疫苗在制备时添加或未添加氢氧化铝和C群多糖(C-ps)。给予12.5至100微克蛋白质的剂量,每隔六周注射两次。所有三种配方的耐受性良好且具有高度免疫原性,可在人体中诱导杀菌和调理抗体。OMV吸附到氢氧化铝上可降低兔子的热原性。不同配方之间的免疫原性差异相对较小,但在第二次给药后,当疫苗吸附时观察到更强的加强反应。因此,含有OMV和C-ps的配方即使不使用氢氧化铝也代表一种安全且高度免疫原性的疫苗。